Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing closer to the ...

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Lunit will use two of its AI-based SCOPE platform to analyze immunohistochemistry slides and the tumor microenvironment.

Anavex had proposed restricting the drug's indication to patients with early Alzheimer's without mutations in the SIGMAR1 gene.